Cell Lysis Market to Surpass US$ 7,335.40 Million by 2030

Global Cell Lysis Market, by Product Type (Instruments and Consumables), by Cell Type (Mammalian Cells, Microbial Cells, and Other Cells), by End User (Academic and Research Labs and Pharmaceutical and Biotechnology Companies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 3,781.33 Million in 2022 and is expected to exhibit a CAGR of 8.6% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.

High prevalence of infectious diseases and cancer is the major factor driving growth of the global cell lysis market over the forecast period. Cell lysis is vital step for study or research in proteomics, as protein can only be extracted if cell lysis process is conducted. Furthermore, cell lysis is crucial step required to be performed for nuclear extraction, after which the DNA is modified using the recombinant DNA technology. Thus, increasing research activities on recombinant DNA technology to examine the functioning of living system by manipulating their genome for production of useful metabolite will fuel growth of the cell lysis market. For instance, recombinant DNA technology has introduced new classes of organism namely Genetically Modified Organism (GMO) or Living Modified Organism (LMO).

Global Cell Lysis Market– Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.

However, the COVID-19 pandemic had a positive impact on the cell lysis market. Cell lysis is a process in which the cell membrane is destroyed in order to release the cell contents such as RNA, DNA, protein or organelles of the cell. For the study of virus or pathogen, cell lysis is an important step to separate the contents of the cell, thus the COVID-19 pandemic had a positive impact on the cell lysis market. Moreover, cell lysis is used in the real-time reverse transcription–polymerase chain reaction (RT PCR) test, so as to isolate RNA. RT–PCR is a nuclear-derived method for detecting the presence of specific genetic material in any pathogen, including a virus. Therefore, due the application of cell lysis in RT-PCR tests and research activities, the COVID-19 pandemic had a positive impact on the cell lysis market

Global Cell Lysis Market: Key Developments

In November 2020, Thermo Fisher Scientific Inc., a leader in serving science, and the Biopharmaceutical Analysis Training Laboratory (BATL) at Northeastern University, committed to enabling innovative biopharmaceutical education, entered into a collaborative agreement to advance analytical capabilities and drive innovation across the biopharmaceutical industry in areas including personalized medicine, monoclonal antibodies, and gene and cell therapies.

In May 2020, Aalto Bio Reagents Ltd., Ireland's only developer of critical raw materials and reagents for diagnostic tests, announced the availability of the first RNA Lysis buffer reagent for the pre-treatment of COVID-19 samples prior to testing.

Browse 31 Market Data Tables and 28 Figures spread through 152 Pages and in-depth TOC on “Global Cell Lysis Market”- Forecast to 2030, Global Cell Lysis Market, by Product Type (Instruments and Consumables), by Cell Type (Mammalian Cells, Microbial Cells, and Other Cells), by End User (Academic and Research Labs and Pharmaceutical and Biotechnology Companies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights related to cell lysis market, click the link below:

https://www.coherentmarketinsights.com/market-insight/cell-lysis-market-741

Moreover, high prevalence of various infectious diseases leads to increasing demand for cell lysis to develop new treatment options rapidly. For instance, in March 2018, Seqirus, a leading flu vaccine manufacturer, announced the plan to commercialize the novel cell-based quadrivalent influenza vaccine (QIVc) across Europe.

Key Takeaways of the Global Cell Lysis Market:

• Global cell lysis market is expected to exhibit a CAGR of 8.6% during the forecast period due to increasing prevalence of cancer. For instance, according to data provided by the Centers for Disease Control and Prevention, 1,752,735 new cancer cases were reported and 599,589 people died of cancer, in the U.S. in 2019.
• Among end users, the Pharmaceutical and Biotechnology Companies segment is estimated to hold a dominant position in the global cell lysis market over the forecast period, as the pharmaceutical and biotechnology companies are employing cell lysis in the research studies for developing treatment options for various diseases such as COVID-19 infection. For instance, in March 2022, CanSinoBIO, a company developing and manufacturing biological vaccine products, announced that its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (trade name: Convidecia) had been approved by the Ministry of Health, Malaysia and the Indonesian National Agency of Drug and Food Control as a heterologous booster.
• On the basis of region, the North America segment is expected to hold a dominant position in the global cell lysis market over the forecast period, owing to increased investments by the government for research and development activities employing cell therapies. For instance, in March 2020, the Government of Canada invested around US$ 6.9 million through the Stem Cell Network’s competitive research funding program to support stem cell research in Canada.
• Major players operating in the global cell lysis market include Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Merck KgaA, QIAGEN, Roche Molecular Systems, Inc., Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., and Qsonica